<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568073</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-301</org_study_id>
    <secondary_id>2010-021860-13</secondary_id>
    <nct_id>NCT01568073</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With &quot;Wearing-off&quot; Phenomenon</brief_title>
  <official_title>Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With &quot;Wearing-off&quot; Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo- and Active-controlled, Parallel-group, Multicentre Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to demonstrate the efficacy and safety of BIA 9-1067, compared with
      entacapone or placebo, when administered with the existing treatment of L-DOPA plus a Dopa
      Decarboxylase Inhibitor (DDCI), in patients with Parkinson's Disease (PD) and end-of-dose
      motor fluctuations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy and safety of BIA 9-1067 in idiopathic Parkinson's disease patients with
      &quot;wearing-off&quot; phenomenon treated with levodopa plus a dopa decarboxylase inhibitor (DDCI): a
      double-blind, randomised, placebo- and active-controlled, parallel-group, multicentre
      clinical study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,</measure>
    <time_frame>14 to 15 weeks</time_frame>
    <description>The primary efficacy variable will be the change from baseline in absolute OFF-time at the end of the DB period, This results refers when administered with the existing treatment of L-DOPA plus a DDCI, in patients with PD and end-of-dose motor fluctuations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total UPDRS SCORE (I, II (ON), and III)</measure>
    <time_frame>14 to 15 weeks</time_frame>
    <description>Total UPDRS (Part I, II (ON) and III)
UPDRS I evaluation of mentation, behavior, and mood
UPDRS II self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food
UPDRS III clinician-scored monitored motor evaluation The UPDRS I, II and III scores and subscores are calculated as the sum of all individual items. If one or two items in a scale are missing, they will be imputed with the mean of the non-missing items of that scale.
Subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe
The final cumulative score will range from 0 (no disability) to 199 (total disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Sleep Scale (PDSS)</measure>
    <time_frame>14 to 15 weeks</time_frame>
    <description>The Parkinson's disease Sleep Scale (PDSS) is a specific scale for the assessment of sleep disturbances in subjects with PD. The PDSS score is calculated as the sum of all single items. If one or two items are missing, they will be imputed with the mean of the non-missing items. If three or more items are missing, no imputation will be done and the score will be set to missing.
Subscale has 0-10 ratings, where 0 = severe and 10 = normal
The PDSS total score is a sum score of all 15 questions and ranges from 0 to 150, with lower scores meaning more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-motor Symptoms Scale (NMSS)</measure>
    <time_frame>14 to 15 weeks</time_frame>
    <description>The Non-motor Symptoms Scale (NMSS) consists of 30 questions, covering 9 dimensions, whereby each item is scored for severity and frequency: Severity None 0 Mild (symptoms present but causes little distress) 1 Moderate (some distress or disturbance to subject) 2 Severe (major source of distress or disturbance to subject) 3
Frequency Rarely (&lt;1/wk) 1 Often (1/wk) 2 Frequent (several times per week) 3 Very Frequent (daily or all the time) 4
The product of frequency and severity is calculated for each item and each dimension score is defined as the sum of the frequency*severity of the respective items. If frequency or severity of a single item is missing, the domain score will not be calculated. The NMSS total score is defined as the sum of all domain scores.
The NMSS total score is calculated by adding all domain scores (0-360), and lower scores mean less disability.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>BIA 9-1067</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC, Opicapone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entacapone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comtan®; Active comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLC, Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 9-1067</intervention_name>
    <description>5, 25 and 50 mg of BIA 9-1067 (once-daily)</description>
    <arm_group_label>BIA 9-1067</arm_group_label>
    <other_name>OPC, Opicapone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entacapone</intervention_name>
    <description>200 mg entacapone (concomitantly with each L-dopa/DDCI dose)</description>
    <arm_group_label>Entacapone</arm_group_label>
    <other_name>Comtan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>200 mg</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>PLC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa</intervention_name>
    <arm_group_label>BIA 9-1067</arm_group_label>
    <arm_group_label>Entacapone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>L-Dopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa</intervention_name>
    <description>DOPA decarboxylase inhibitor</description>
    <arm_group_label>BIA 9-1067</arm_group_label>
    <arm_group_label>Entacapone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benserazide</intervention_name>
    <description>DOPA decarboxylase inhibitor</description>
    <arm_group_label>BIA 9-1067</arm_group_label>
    <arm_group_label>Entacapone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        V1 (Screening, up to 14 days before V2)

          -  Able to comprehend and willing to sign an informed consent form.

          -  Male and female subjects between 30 and 83 years old, inclusive.

          -  Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain
             Bank Clinical Diagnostic Criteria for at least 3 years.

          -  Disease severity Stages I-III (modified Hoehn &amp;Yahr staging) at ON.

          -  Treated with L-DOPA/DDCI for at least 1 year with clear clinical improvement as per
             investigator's judgment.

          -  Treated with 3 to 8 daily doses of L-DOPA/DDCI, which can include a slow-release
             formulation.

          -  On a stable regimen of L-DOPA/DDCI and other anti-PD drugs for at least 4 weeks before
             screening.

          -  Signs of &quot;wearing-off&quot; phenomenon (end-of-dose deterioration) for a minimum of 4 weeks
             before screening, with average total daily OFF time while awake of at least 1.5 hours,
             excluding the early morning pre-first dose OFF, despite optimal anti-PD therapy (based
             on the investigator's judgment).

          -  Able to keep reliable diaries of motor fluctuations (alone or with family/caregiver
             assistance).

          -  Amenorrheic for at least 1 year or surgically sterile for at least 6 months before
             screening. Females of childbearing potential must be using an effective non-hormonal
             contraceptive method.

        V2 (Randomisation, Day 0)

          -  Have filled-in self-rating diary charts in accordance with the diary chart
             instructions and with ≤ 3 errors per day.

          -  At least 1.5 OFF hours per day, excluding the early morning pre-first dose OFF period
             (i.e. the time between wake-up and response to the first L DOPA/DDCI dosage), as
             recorded in the self-rating diary for at least 2 of the 3 days preceding V2.

          -  Results of the screening laboratory tests are considered acceptable by the
             investigator (i.e. not clinically relevant for the well-being of the subject or for
             the purpose of the study).

        Exclusion Criteria:

        V1 (Screening, up to 14 days before V2)

          -  Non-idiopathic PD (atypical parkinsonism, secondary [acquired or symptomatic]
             parkinsonism, Parkinson-plus syndrome).

          -  Dyskinesia disability score &gt; 3 in the Unified Parkinson's Disease Rating Scale
             (UPDRS) Sub-section IV A, item 33.

          -  Severe and/or unpredictable OFF periods.

          -  Treatment with prohibited medication: tolcapone, neuroleptics, venlafaxine, monoamine
             oxidase inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25
             mg/day in buccal absorption formulation or rasagiline up to 1 mg/day), or antiemetics
             with antidopaminergic action (except domperidone) within the month before screening.

          -  Previous use of entacapone.

          -  Treatment with apomorphine, alpha-methyldopa, or reserpine within the month before
             screening or likely to be needed at any time during the study.

          -  Dosage change of concomitant anti-PD medication within 4 weeks of screening.

          -  Previous or planned (during the entire study duration, including the OL period) deep
             brain stimulation.

          -  Previous stereotactic surgery (e.g. pallidotomy, thalamotomy) for PD or with planned
             stereotactic surgery during the study period.

          -  Any IMP within the 3 months (or within 5 half-lives, whichever is longer) before
             screening.

          -  Any medical condition that might place the subject at increased risk or interfere with
             assessments.

          -  Past (within the past year) or present history of suicidal ideation or suicide
             attempts.

          -  Current or previous (within the past year) diagnosis of major depressive disorder,
             mania, bipolar disorder, psychosis, dysthymia, generalised anxiety disorder, alcohol
             or substance abuse excluding caffeine or nicotine, impulse control disorders (e.g.
             pathological gambling), dementia or eating disorders according to Diagnostic and
             Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV) American
             Psychiatric Association, 2000 criteria, as determined by the investigator.

          -  A clinically relevant electrocardiogram (ECG) abnormality (relevance should be
             assessed by a cardiologist if needed).

          -  Current evidence of unstable cardiovascular disease, including but not limited to
             uncontrolled hypertension, myocardial infarction with important systolic or diastolic
             dysfunction, unstable angina, congestive heart failure (New York Heart Association
             class ≥ III), and significant cardiac arrhythmia (Mobitz II 2nd or 3rd degree AV block
             or any other arrhythmia causing haemodynamic repercussions as symptomatic bradycardia
             or syncope).

          -  Prior renal transplant or current renal dialysis.

          -  Pheochromocytoma, paraganglioma, or other catecholamine secretive neoplasm.

          -  Known hypersensitivity to the ingredients of IMPs used.

          -  History of neuroleptic malignant syndrome (NMS) or NMS-like syndromes, or
             non-traumatic rhabdomyolysis.

          -  History of or current cancer disease, which in the investigator's opinion would
             exclude the subject from the study (e.g. melanoma, prostate cancer).

          -  Unstable active narrow-angle or unstable wide-angle glaucoma.

          -  History of or current evidence of any relevant disease in the context of this study,
             i.e. with respect to the safety of the subject or related to the study conditions,
             e.g. which may influence the absorption or metabolism (such as a relevant liver
             disease) of the IMP.

          -  Pregnant or breastfeeding. V2 (Randomisation, Day 0)

          -  Any abnormality in the liver enzymes (alanine aminotransferase and/or aspartate
             aminotransferase) &gt; 2 times the upper limit of the normal range, in the screening
             laboratory tests results.

          -  Plasma sodium &lt; 130 mmol/L, white blood cell count &lt; 3000 cells/mm3, or any other
             relevant clinical laboratory abnormality in the screening laboratory tests results
             that, in the investigator's opinion, may compromise the subject's safety.

          -  Inadequate compliance to concomitant L-DOPA/DDCI and other anti-PD drugs during the
             Screening period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>83 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquim Ferreira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar de Lisboa Norte, EPE - Hospital de Staª Maria-Centro de Estudos Egas Moniz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bial - Portela &amp; Cª, S.A.</name>
      <address>
        <city>S. Mamede do Coronado</city>
        <zip>4745-457</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <results_first_submitted>November 26, 2014</results_first_submitted>
  <results_first_submitted_qc>January 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2015</results_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson</keyword>
  <keyword>PD</keyword>
  <keyword>Wearing-off</keyword>
  <keyword>Levodopa/DDCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Opicapone</mesh_term>
    <mesh_term>Entacapone</mesh_term>
    <mesh_term>Benserazide</mesh_term>
    <mesh_term>Dopa Decarboxylase</mesh_term>
    <mesh_term>Aromatic Amino Acid Decarboxylase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo 200 mg</description>
        </group>
        <group group_id="P2">
          <title>Entacapone</title>
          <description>Entacapone - 200 mg</description>
        </group>
        <group group_id="P3">
          <title>OPC 5mg</title>
          <description>OPC, Opicapone 5mg</description>
        </group>
        <group group_id="P4">
          <title>OPC 25mg</title>
          <description>OPC, Opicapone 25mg</description>
        </group>
        <group group_id="P5">
          <title>OPC 50mg</title>
          <description>OPC, Opicapone 50mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="119"/>
                <participants group_id="P5" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="110"/>
                <participants group_id="P4" count="108"/>
                <participants group_id="P5" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo 200 mg</description>
        </group>
        <group group_id="B2">
          <title>Entacapone</title>
          <description>Entacapone - 200 mg</description>
        </group>
        <group group_id="B3">
          <title>OPC 5mg</title>
          <description>OPC, Opicapone 5mg</description>
        </group>
        <group group_id="B4">
          <title>OPC 25mg</title>
          <description>OPC, Opicapone 25mg</description>
        </group>
        <group group_id="B5">
          <title>OPC 50mg</title>
          <description>OPC, Opicapone 50mg</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="122"/>
            <count group_id="B4" value="119"/>
            <count group_id="B5" value="116"/>
            <count group_id="B6" value="600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="81"/>
                    <measurement group_id="B6" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,</title>
        <description>The primary efficacy variable will be the change from baseline in absolute OFF-time at the end of the DB period, This results refers when administered with the existing treatment of L-DOPA plus a DDCI, in patients with PD and end-of-dose motor fluctuations</description>
        <time_frame>14 to 15 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 200 mg</description>
          </group>
          <group group_id="O2">
            <title>Entacapone</title>
            <description>Entacapone - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>OPC 5mg</title>
            <description>OPC, Opicapone 5mg</description>
          </group>
          <group group_id="O4">
            <title>OPC 25mg</title>
            <description>OPC, Opicapone 25mg</description>
          </group>
          <group group_id="O5">
            <title>OPC 50mg</title>
            <description>OPC, Opicapone 50mg</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,</title>
          <description>The primary efficacy variable will be the change from baseline in absolute OFF-time at the end of the DB period, This results refers when administered with the existing treatment of L-DOPA plus a DDCI, in patients with PD and end-of-dose motor fluctuations</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="105"/>
                <count group_id="O5" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.0" spread="13.38"/>
                    <measurement group_id="O2" value="-96.3" spread="13.40"/>
                    <measurement group_id="O3" value="-91.3" spread="13.46"/>
                    <measurement group_id="O4" value="-85.9" spread="13.69"/>
                    <measurement group_id="O5" value="-116.8" spread="13.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total UPDRS SCORE (I, II (ON), and III)</title>
        <description>Total UPDRS (Part I, II (ON) and III)
UPDRS I evaluation of mentation, behavior, and mood
UPDRS II self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food
UPDRS III clinician-scored monitored motor evaluation The UPDRS I, II and III scores and subscores are calculated as the sum of all individual items. If one or two items in a scale are missing, they will be imputed with the mean of the non-missing items of that scale.
Subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe
The final cumulative score will range from 0 (no disability) to 199 (total disability).</description>
        <time_frame>14 to 15 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 200 mg</description>
          </group>
          <group group_id="O2">
            <title>Entacapone</title>
            <description>Entacapone - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>OPC 5mg</title>
            <description>OPC, Opicapone 5mg</description>
          </group>
          <group group_id="O4">
            <title>OPC 25mg</title>
            <description>OPC, Opicapone 25mg</description>
          </group>
          <group group_id="O5">
            <title>OPC 50mg</title>
            <description>OPC, Opicapone 50mg</description>
          </group>
        </group_list>
        <measure>
          <title>Total UPDRS SCORE (I, II (ON), and III)</title>
          <description>Total UPDRS (Part I, II (ON) and III)
UPDRS I evaluation of mentation, behavior, and mood
UPDRS II self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food
UPDRS III clinician-scored monitored motor evaluation The UPDRS I, II and III scores and subscores are calculated as the sum of all individual items. If one or two items in a scale are missing, they will be imputed with the mean of the non-missing items of that scale.
Subscale has 0-4 ratings, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe
The final cumulative score will range from 0 (no disability) to 199 (total disability).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="111"/>
                <count group_id="O5" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" spread="16.56"/>
                    <measurement group_id="O2" value="35.4" spread="19.98"/>
                    <measurement group_id="O3" value="38.2" spread="16.16"/>
                    <measurement group_id="O4" value="40.1" spread="18.56"/>
                    <measurement group_id="O5" value="38.8" spread="18.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (14 to 15 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="14.87"/>
                    <measurement group_id="O2" value="29.8" spread="18.69"/>
                    <measurement group_id="O3" value="31.0" spread="15.98"/>
                    <measurement group_id="O4" value="32.0" spread="15.61"/>
                    <measurement group_id="O5" value="31.5" spread="18.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="10.03"/>
                    <measurement group_id="O2" value="-6.0" spread="11.69"/>
                    <measurement group_id="O3" value="-7.6" spread="9.96"/>
                    <measurement group_id="O4" value="-7.6" spread="9.76"/>
                    <measurement group_id="O5" value="-6.5" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parkinson's Disease Sleep Scale (PDSS)</title>
        <description>The Parkinson’s disease Sleep Scale (PDSS) is a specific scale for the assessment of sleep disturbances in subjects with PD. The PDSS score is calculated as the sum of all single items. If one or two items are missing, they will be imputed with the mean of the non-missing items. If three or more items are missing, no imputation will be done and the score will be set to missing.
Subscale has 0-10 ratings, where 0 = severe and 10 = normal
The PDSS total score is a sum score of all 15 questions and ranges from 0 to 150, with lower scores meaning more disability.</description>
        <time_frame>14 to 15 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 200 mg</description>
          </group>
          <group group_id="O2">
            <title>Entacapone</title>
            <description>Entacapone - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>OPC 5mg</title>
            <description>OPC, Opicapone 5mg</description>
          </group>
          <group group_id="O4">
            <title>OPC 25mg</title>
            <description>OPC, Opicapone 25mg</description>
          </group>
          <group group_id="O5">
            <title>OPC 50mg</title>
            <description>OPC, Opicapone 50mg</description>
          </group>
        </group_list>
        <measure>
          <title>Parkinson's Disease Sleep Scale (PDSS)</title>
          <description>The Parkinson’s disease Sleep Scale (PDSS) is a specific scale for the assessment of sleep disturbances in subjects with PD. The PDSS score is calculated as the sum of all single items. If one or two items are missing, they will be imputed with the mean of the non-missing items. If three or more items are missing, no imputation will be done and the score will be set to missing.
Subscale has 0-10 ratings, where 0 = severe and 10 = normal
The PDSS total score is a sum score of all 15 questions and ranges from 0 to 150, with lower scores meaning more disability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" spread="24.97"/>
                    <measurement group_id="O2" value="100.7" spread="25.46"/>
                    <measurement group_id="O3" value="97.8" spread="22.55"/>
                    <measurement group_id="O4" value="92.7" spread="26.85"/>
                    <measurement group_id="O5" value="98.0" spread="22.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" spread="24.20"/>
                    <measurement group_id="O2" value="102.5" spread="26.20"/>
                    <measurement group_id="O3" value="103.8" spread="22.08"/>
                    <measurement group_id="O4" value="101.7" spread="23.92"/>
                    <measurement group_id="O5" value="100.2" spread="24.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" spread="25.30"/>
                    <measurement group_id="O2" value="103.2" spread="24.86"/>
                    <measurement group_id="O3" value="102.8" spread="22.78"/>
                    <measurement group_id="O4" value="100.6" spread="23.75"/>
                    <measurement group_id="O5" value="100.7" spread="24.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (14 to 15 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" spread="25.81"/>
                    <measurement group_id="O2" value="102.8" spread="24.98"/>
                    <measurement group_id="O3" value="102.9" spread="22.61"/>
                    <measurement group_id="O4" value="100.4" spread="23.75"/>
                    <measurement group_id="O5" value="100.9" spread="24.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-motor Symptoms Scale (NMSS)</title>
        <description>The Non-motor Symptoms Scale (NMSS) consists of 30 questions, covering 9 dimensions, whereby each item is scored for severity and frequency: Severity None 0 Mild (symptoms present but causes little distress) 1 Moderate (some distress or disturbance to subject) 2 Severe (major source of distress or disturbance to subject) 3
Frequency Rarely (&lt;1/wk) 1 Often (1/wk) 2 Frequent (several times per week) 3 Very Frequent (daily or all the time) 4
The product of frequency and severity is calculated for each item and each dimension score is defined as the sum of the frequency*severity of the respective items. If frequency or severity of a single item is missing, the domain score will not be calculated. The NMSS total score is defined as the sum of all domain scores.
The NMSS total score is calculated by adding all domain scores (0–360), and lower scores mean less disability.</description>
        <time_frame>14 to 15 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 200 mg</description>
          </group>
          <group group_id="O2">
            <title>Entacapone</title>
            <description>Entacapone - 200 mg</description>
          </group>
          <group group_id="O3">
            <title>OPC 5mg</title>
            <description>OPC, Opicapone 5mg</description>
          </group>
          <group group_id="O4">
            <title>OPC 25mg</title>
            <description>OPC, Opicapone 25mg</description>
          </group>
          <group group_id="O5">
            <title>OPC 50mg</title>
            <description>OPC, Opicapone 50mg</description>
          </group>
        </group_list>
        <measure>
          <title>Non-motor Symptoms Scale (NMSS)</title>
          <description>The Non-motor Symptoms Scale (NMSS) consists of 30 questions, covering 9 dimensions, whereby each item is scored for severity and frequency: Severity None 0 Mild (symptoms present but causes little distress) 1 Moderate (some distress or disturbance to subject) 2 Severe (major source of distress or disturbance to subject) 3
Frequency Rarely (&lt;1/wk) 1 Often (1/wk) 2 Frequent (several times per week) 3 Very Frequent (daily or all the time) 4
The product of frequency and severity is calculated for each item and each dimension score is defined as the sum of the frequency*severity of the respective items. If frequency or severity of a single item is missing, the domain score will not be calculated. The NMSS total score is defined as the sum of all domain scores.
The NMSS total score is calculated by adding all domain scores (0–360), and lower scores mean less disability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="115"/>
                <count group_id="O5" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="29.20"/>
                    <measurement group_id="O2" value="32.1" spread="25.09"/>
                    <measurement group_id="O3" value="36.1" spread="26.67"/>
                    <measurement group_id="O4" value="39.8" spread="30.18"/>
                    <measurement group_id="O5" value="36.4" spread="28.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" spread="27.91"/>
                    <measurement group_id="O2" value="27.9" spread="21.53"/>
                    <measurement group_id="O3" value="30.2" spread="24.36"/>
                    <measurement group_id="O4" value="34.0" spread="24.83"/>
                    <measurement group_id="O5" value="30.2" spread="21.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3" spread="25.75"/>
                    <measurement group_id="O2" value="27.5" spread="21.91"/>
                    <measurement group_id="O3" value="29.5" spread="24.30"/>
                    <measurement group_id="O4" value="34.6" spread="25.39"/>
                    <measurement group_id="O5" value="33.7" spread="30.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="25.71"/>
                    <measurement group_id="O2" value="27.5" spread="21.82"/>
                    <measurement group_id="O3" value="29.5" spread="24.30"/>
                    <measurement group_id="O4" value="34.4" spread="25.32"/>
                    <measurement group_id="O5" value="33.4" spread="30.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo 200 mg</description>
        </group>
        <group group_id="E2">
          <title>Entacapone</title>
          <description>Entacapone - 200 mg</description>
        </group>
        <group group_id="E3">
          <title>OPC 5mg</title>
          <description>OPC, Opicapone 5mg</description>
        </group>
        <group group_id="E4">
          <title>OPC 25mg</title>
          <description>OPC, Opicapone 25mg</description>
        </group>
        <group group_id="E5">
          <title>OPC 50mg</title>
          <description>OPC, Opicapone 50mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>COR PULMONALE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISUAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>HEPATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>NEAR DROWNING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>BENIGN EAR NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>BOWEN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>SUPERFICIAL SPREADING MELANOMA STAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DYSKINESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URINARY TRACT INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DYSKINESIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

